The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Facility designed to advance the next generation of imaging systems
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
The centre works with active pharmaceutical ingredients (APIs) and can utilize innovative concepts with model APIs
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Subscribe To Our Newsletter & Stay Updated
